Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CNBX Pharmaceuticals Inc. (CNBX)
Bethesda, MD, US
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -50.00% | -50.00% | -85.19% | -99.02% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+84.8% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +11.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+199.7% Q1'26: +2,800.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.37× Q1'26: -0.26× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cannabics, Inc. | 20.50M | 51.00% | 20.50M | — | — | — | CO | DELAWARE | 2014-06-25 | ↗ |
| 2 | Ophion Management Ltd. | 20.00M | 99.00% | 20.00M | — | 20.00M | 10.00 | CO | Canadian | 2013-07-03 | ↗ |
| 3 | Cannabics Pharmaceuticals, Inc. | 900.0K | 9.60% | 900.0K | — | 900.0K | — | CO | Delaware | 2019-03-27 | ↗ |
| 4 | S | 239.0K | 9.98% | — | 239.0K | — | 239.0K | OO | Delaware, United States | 2023-03-06 | ↗ |
| 5 | Thomas Mills | — | 0.00% | — | — | — | 10.00 | IN | Canadian | 2014-05-01 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-07-25 | Cannabics Inc. | 10% Owner | S-Sale | A | COMMON STOCK | 18,239,594 | 0.00 | — | 88,289,594 | — | ↗ |
| 2014-06-23 | Cannabics Inc. | 10% Owner | S-Sale | A | Common Stock | 14,525,000 | 0.01 | 140.9K | 35,025,000 | — | ↗ |
| 2014-05-08 | MILLS THOMAS E | 10% Owner | S-Sale | D | common stock | 20,500,000 | 0.01 | 198.9K | 3 | — | ↗ |
| 2014-05-08 | Cannabics Inc. | 10% Owner | S-Sale | A | Common Stock | 20,500,000 | 0.01 | 198.9K | 20,500,000 | — | ↗ |
| 2014-04-25 | MILLS THOMAS E | 10% Owner | S-Sale | A | common stock | 20,500,000 | 0.01 | 198.9K | 0 | — | ↗ |
| 2013-10-28 | MILLS THOMAS E | 10% Owner | P-Purchase | A | COMMON STOCK | 20,000,000 | 100,000.00 | 2.00T | 20,510,000 | — | ↗ |
| 2013-06-28 | MILLS THOMAS E | 10% Owner | J-Other | D | common stock | 20,000,000 | 0.01 | 100.0K | 510,000 | — | ↗ |
| 2013-06-24 | MILLS THOMAS E | 10% Owner | P-Purchase | A | common stock | 20,000,000 | 0.01 | 100.0K | 20,510,000 | — | ↗ |
| 2011-11-08 | North American Mining Corp | 10% Owner | J-Other | D | common stock | 31,000,000 | 0.00 | — | 0 | — | ↗ |
| 2011-05-31 | North American Mining Corp | 10% Owner | — | D | common stock | 0 | 0.00 | — | 31,000,000 | — | ↗ |
| 2007-09-25 | MILLS THOMAS E | Director / Officer / 10% Owner | P-Purchase | A | common | 2,000,000 | 0.00 | 5.0K | 10,000,000 | — | ↗ |
| 2007-09-25 | HILFORD LOU | 10% Owner | S-Sale | D | common | 2,000,000 | 0.00 | 5.0K | 0 | — | ↗ |
| 2006-04-13 | HILFORD LOU | Director / Officer | — | D | common stock | 0 | 0.00 | — | 2,000,000 | — | ↗ |
| 2006-04-12 | MILLS THOMAS E | Director / Officer | — | D | common stock | 0 | 0.00 | — | 8,000,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gabriel Yariv | President, Chief Operating Officer & Executive Chairman | 188.0K | male |
| Eyal Barad | Co-Founder, Chief Executive Officer & Director | 45.9K | male |
| Uri Ben-Or | Chief Financial Officer | 34.2K | male |
| Sigalit Ariely-Portnoy | Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board | — | — |
| Tal Mofkadi | Financial Advisor & Member of Advisory Board | — | — |
| Yaakov Waksman | Head of Cannabidiol Research | — | — |
| Yasha Borstein | Chief Data Officer | — | male |
| Ilya Reznik | Head of Neuropsychiatry Development | — | — |
| Lior Eshdat | Member of Scientific Advisory Board & Vice President of IP | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CNBX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
